Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer

  1. Sakari Vanharanta
  2. Christina B Marney
  3. Weiping Shu
  4. Manuel Valiente
  5. Yilong Zou
  6. Aldo Mele
  7. Robert B Darnell
  8. Joan Massagué  Is a corresponding author
  1. Memorial Sloan-Kettering Cancer Center, United States
  2. The Rockefeller University, United States

Abstract

The mechanisms through which cancer cells lock in altered transcriptional programs in support of metastasis remain largely unknown. Through integrative analysis of clinical breast cancer gene expression datasets, cell line models of breast cancer progression, and mutation data from cancer genome resequencing studies, we identified RNA binding motif protein 47 (RBM47) as a suppressor of breast cancer progression and metastasis. RBM47 inhibited breast cancer re-initiation and growth in experimental models. Transcriptome-wide HITS-CLIP analysis revealed widespread RBM47 binding to mRNAs, most prominently in introns and 3'UTRs. RBM47 altered splicing and abundance of a subset of its target mRNAs. Some of the mRNAs stabilized by RBM47, as exemplified by dickkopf WNT signaling pathway inhibitor 1, inhibit tumor progression downstream of RBM47. Our work identifies RBM47 as an RNA-binding protein that can suppress breast cancer progression and demonstrates how the inactivation of a broadly targeted RNA chaperone enables selection of a pro-metastatic state.

Article and author information

Author details

  1. Sakari Vanharanta

    Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  2. Christina B Marney

    The Rockefeller University, New York, United States
    Competing interests
    No competing interests declared.
  3. Weiping Shu

    Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  4. Manuel Valiente

    Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  5. Yilong Zou

    Memorial Sloan-Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  6. Aldo Mele

    The Rockefeller University, New York, United States
    Competing interests
    No competing interests declared.
  7. Robert B Darnell

    The Rockefeller University, New York, United States
    Competing interests
    Robert B Darnell, Reviewing editor, eLife.
  8. Joan Massagué

    Memorial Sloan-Kettering Cancer Center, New York, United States
    For correspondence
    j-massague@ski.mskcc.org
    Competing interests
    Joan Massagué, Reviewing editor, eLife.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#99-09-032) of Memorial Sloan Kettering Cancer Center. All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.

Copyright

© 2014, Vanharanta et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,469
    views
  • 676
    downloads
  • 106
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sakari Vanharanta
  2. Christina B Marney
  3. Weiping Shu
  4. Manuel Valiente
  5. Yilong Zou
  6. Aldo Mele
  7. Robert B Darnell
  8. Joan Massagué
(2014)
Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer
eLife 3:e02734.
https://doi.org/10.7554/eLife.02734

Share this article

https://doi.org/10.7554/eLife.02734

Further reading

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Bethany M Bartlett, Yatendra Kumar ... Wendy A Bickmore
    Research Article Updated

    During oncogene-induced senescence there are striking changes in the organisation of heterochromatin in the nucleus. This is accompanied by activation of a pro-inflammatory gene expression programme – the senescence-associated secretory phenotype (SASP) – driven by transcription factors such as NF-κB. The relationship between heterochromatin re-organisation and the SASP has been unclear. Here, we show that TPR, a protein of the nuclear pore complex basket required for heterochromatin re-organisation during senescence, is also required for the very early activation of NF-κB signalling during the stress-response phase of oncogene-induced senescence. This is prior to activation of the SASP and occurs without affecting NF-κB nuclear import. We show that TPR is required for the activation of innate immune signalling at these early stages of senescence and we link this to the formation of heterochromatin-enriched cytoplasmic chromatin fragments thought to bleb off from the nuclear periphery. We show that HMGA1 is also required for cytoplasmic chromatin fragment formation. Together these data suggest that re-organisation of heterochromatin is involved in altered structural integrity of the nuclear periphery during senescence, and that this can lead to activation of cytoplasmic nucleic acid sensing, NF-κB signalling, and activation of the SASP.